DOCSLIB.ORG

Transcript of Proceedings

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Transcript of Proceedings TRANSCRIPT OF PROCEEDINGS IN THE MATTER OF: ) ) BACTERIOPHAGE THERAPY: ) SCIENTIFIC AND REGULATORY ISSUES ) PUBLIC WORKSHOP ) (This transcript has not been edited or corrected, but appears as received from the commercial transcribing service. Accordingly the Food and Drug Administration makes no representation as to its accuracy.) Pages: 301 through 532 Place: Rockville, Maryland Date: July 11, 2017 HERITAGE REPORTING CORPORATION Official Reporters 1220 L Street, N.W., Suite 206 Washington, D.C. 20005-4018 (202) 628-4888 [email protected] 301 BEFORE THE DEPARTMENT OF HEALTH AND HUMAN SERVICES U.S. FOOD AND DRUG ADMINISTRATION IN THE MATTER OF: ) ) BACTERIOPHAGE THERAPY: ) SCIENTIFIC AND REGULATORY ISSUES ) PUBLIC WORKSHOP ) Room 1D-13 NIAID Conference Center 5601 Fishers Lane Rockville, Maryland Tuesday, July 11, 2017 The parties met, pursuant to the notice, at 8:30 a.m. MODERATOR: RYAN RANALLO, Ph.D. NIAID PARTICIPANTS: BISWAJIT BISWAS, Ph.D. Naval Medical Research Center Frederick, Maryland ANDREW CAMILLI, Ph.D. Tufts University BRECK DUERKOP, Ph.D. University of Colorado MICHAEL KURILLA, Ph.D. Office of Biodefense, Research Resources, and Translational Research NIAID Heritage Reporting Corporation (202) 628-4888 302 PARTICIPANTS: (Cont'd.) TIMOTHY LU, MD, Ph.D. Massachusetts Institute of Technology JAMES REGEIMBAL, Ph.D. U.S. Naval Medical Research Unit Lima, Peru ROY STEVENS, DDS Temple University SCOTT STIBITZ, Ph.D. Center for Biologics Evaluation and Research, FDA STUART TYNER, Ph.D. Walter Reed Army Institute of Research PAUL TURNER, Ph.D. Yale University MICHAEL ZAPOR, MD, Ph.D. Walter Reed Army Institute of Research Heritage Reporting Corporation (202) 628-4888 303 C O N T E N T S SESSION 3: Future Directions PAGE The Potential Therapeutic Use of Bacteriophages 305 as Adjuncts or Alternatives to Antibiotics, Michael Zapor and Stuart Tyner Phage Receptors and Resistance Mechanisms in 328 Enterococci, Breck Duerkop Using Phage to Select for Evolution of 350 Reduced Virulence in Pathogenic Bacteria, Paul Turner Engineering Phage and Phage Products to Disrupt 378 Enterococcus faecalis Biofilms, Roy Stevens Engineered Phages for Diagnostics and Therapeutics 398 Timothy Lu Prophylactic Use of Bacteriophages Against 431 Cholera, Andrew Camilli Rapid Emergence of Phage-Resistant Bacteria during 456 Phage Therapy of a Terminally Ill Patient Who Was Infected with Multidrug-resistant A. baumannii, Biswajit Biswas Phage Therapy Against MDR Strains: Overcoming 477 the Double-edged Sword of Phage Specificity, James Regeimbal Panel Discussion Session 3 speakers, with Scott Stibitz, FDA/CBER 513 Concluding Remarks, 527 Michael Kurilla, NIAID Heritage Reporting Corporation (202) 628-4888 304 1 P R O C E E D I N G S 2 (8:30 a.m.) 3 DR. RANALLO: Good morning, everybody. 4 Sorry about that. Good morning. I hope everybody's 5 up. Okay. So we're going to start on time today. My 6 name is Ryan Ranallo, I'm a program officer here, at 7 NIAID, and I'm going to be your moderator for the 8 entire day today, something the organizing committee 9 didn't tell me before they signed me up for this. 10 Nevertheless, hopefully we'll get through it all day 11 today. 12 So one thing that I wanted to just note is 13 how in two years, how things have changed 14 significantly since the last time we've held a phage 15 therapy meeting, and so, with that, I think we have a 16 couple of large buckets of topics today, phage 17 engineering being one of them, and essentially looking 18 at phage for different uses, including, you know, 19 transmission and decolonization. 20 So, with that -- oh, the only other thing I 21 would say is if you have any questions about whether 22 or not your slides have been loaded for speakers, 23 please check in the back. Marcus has been great all 24 day yesterday, and certainly today as well. So for 25 the first talk, it's a tag team talk of Col. Zapor and Heritage Reporting Corporation (202) 628-4888 305 1 Lt. Col. Tyner. 2 Col. Zapor is the deputy commander of 3 operations at the Walter Reed Army Institute of 4 Research, and Lt. Col. Tyner, who I first met actually 5 when I was a post-doc at NCI and -- in Building 37, is 6 the director of bacterial diseases branch, which just 7 actually happens to be my old department where I spent 8 10 years at Walter Reed working on enteric vaccines. 9 So, without further ado, I'm going to introduce Col. 10 Zapor and Lt. Col. Tyner for our first talk. 11 DR. ZAPOR: Okay. Good morning, everybody. 12 Thanks to the organizers for inviting me to speak at 13 this conference. Unfortunately, I'm only here for the 14 morning session because of conflicting obligations, as 15 well as secondary to car problems, but -- so I'll be 16 here until lunch and then depart after that. 17 As you heard, I'm splitting my 30-minute 18 block with a colleague, Lt. Col. Tyner, so I'll be 19 cognizant of the fact that I have 15 minutes to speak 20 to ensure that he has 15 minutes as well. 21 So the purpose of this talk, I was asked to 22 speak about potential therapeutic indications for 23 bacteriophages and first thought we would kind of 24 address some of the limitations of the current -- 25 antibiotics and the current problems. Heritage Reporting Corporation (202) 628-4888 306 1 So antibiotics of course have been the 2 mainstay of therapy in the -- for the treatment of 3 infections for decades, but there have been some 4 unintended consequences. Everybody of course is 5 familiar with the issue of the emergence of multidrug- 6 resistant organisms, in some cases extremely drug- 7 resistant organisms, or even pan drug resistance. 8 Moreover, antibiotics, as effective as they 9 are, are not 100 percent specific. In the parlance of 10 my profession, we unfortunately see considerable 11 friendly fire, especially with the broad-spectrum 12 antibiotics such as the carbapenems, and so oftentimes 13 the antibiotics are effective in eradicating the 14 intended target, but have the unintended consequence 15 of killing benign, or even beneficial, bacteria as 16 well. 17 This is evidenced, for example, by the 18 emergence of C. diff colitis in patients who are on 19 broad spectrum antibiotics. 20 Other limitations with antibiotic use of 21 course include the emergence of drug resistance. I've 22 already spoken to that. Some types of infections are 23 less amenable to treatment than other types. So 24 infections which involve abscesses or other sequestra, 25 antibiotics generally don't penetrate abscess fluid Heritage Reporting Corporation (202) 628-4888 307 1 very well, some less well than others. Rifampin works 2 fairly well, but there are many other antibiotics that 3 are inactivated in abscess fluid. Aminoglycosides 4 come to mind. 5 Additionally, the presence of a foreign body 6 can make infections difficult to treat. Foreign body 7 -- we've seen a considerable number, a very large 8 number, of war wounded coming back from Iraq and 9 Afghanistan status post blast injuries with retained 10 foreign bodies. Some of these can be removed 11 surgically, some cannot. Some are intentionally left 12 in place. 13 Each of these FBs becomes a potential nidus 14 for infection. They get colonized with bacteria, 15 oftentimes bacteria that elaborate glycocalyces or 16 make a biofilm, and there are very few antibiotics 17 that can reliably sterilize biofilms. 18 Other considerations include patient anatomy. So I 19 gave the analogy or offered the example of war 20 wounded. Patients who have had blast injuries 21 oftentimes have interruptions in their blood supply, 22 they have interrupted vasculature, and all the tissue 23 prior, distal to the injury becomes ischemic, starved 24 for oxygen, starved for blood, and antibiotics can 25 only work where they're delivered, and if antibiotics Heritage Reporting Corporation (202) 628-4888 308 1 are not delivered to vascularized, oxygenated tissue, 2 then they don't work very well. It's very common for 3 us to see patients who have ischemic limbs, necrotic 4 tissue, retained foreign bodies, and antibiotics just 5 don't work very well. More often than not the 6 intervention of choice for those patients is cold 7 steel, for example, amputation, rather than medical 8 therapy alone. 9 And then there are other considerations such 10 as the rapid metabolizers. We know that there are 11 some patients who just inherently metabolize and 12 inactivate antibiotics and other drugs more rapidly 13 than other patients. 14 And then we always have to be cognizant of 15 patients who have drug allergies or some other 16 contraindication to antibiotics. So, examples that 17 come to mind, beta lactam allergies, which are fairly 18 common, nephrotoxicity associated with 19 aminoglycosides, associated with vancomycin and so 20 forth. 21 So, for all these reasons, antibiotics, as 22 effective as they are, as reliable as they have been, 23 they do have their limitations, and, as a consequence, 24 we're forced to explore alternatives. 25 So what are some of the pros and cons of Heritage Reporting Corporation (202) 628-4888 309 1 using phages as therapy? This is a table I put 2 together with which you may or may not agree. In the 3 pro column for phages there's long history of use. 4 Everybody knows that phage has been used in Eastern 5 Europe for many years, and at one point in time early 6 in the 20th Century, phages of course were available 7 by prescription in this country.
Load more

Recommended publications
  • Phagemid-Based Method of Producing Filamentous Bacteriophage Particles Displaying Antibody Molecules and the Corresponding Bacteriophage Particles
    Europäisches Patentamt *EP001433846A2* (19) European Patent Office Office européen des brevets (11) EP 1 433 846 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C12N 15/10, C07K 16/00, 30.06.2004 Bulletin 2004/27 C12N 15/62, C12N 7/00, C12N 15/73 (21) Application number: 04005419.9 (22) Date of filing: 10.07.1991 (84) Designated Contracting States: • Griffiths, Andrew David AT BE CH DE DK ES FR GB GR IT LI LU NL SE Cambridge CB1 4AY (GB) • Jackson, Ronald Henry (30) Priority: 10.07.1990 GB 9015198 Cambridge CB1 2NU (GB) 19.10.1990 GB 9022845 • Holliger, Kaspar Philipp 12.11.1990 GB 9024503 Cambridge CB1 4HT (GB) 06.03.1991 GB 9104744 • Marks, James David 15.05.1991 GB 9110549 Kensington, CA 94707-1310 (US) • Clackson, Timothy Piers (62) Document number(s) of the earlier application(s) in Somerville, MA 02143 (US) accordance with Art. 76 EPC: • Chiswell, David John 97120149.6 / 0 844 306 Buckingham MK18 2LD (GB) 96112510.1 / 0 774 511 • Winter, Gregory Paul Cambridge CB2 1TQ (GB) (71) Applicants: • Bonnert, Timothy Peter • Cambridge Antibody Technology LTD Seattle, WA 98102 (US) Cambridge CB1 6GH (GB) • Medical Research Council (74) Representative: Walton, Seán Malcolm et al London W1B 1AL (GB) Mewburn Ellis LLP York House, (72) Inventors: 23 Kingsway • McCafferty, John London WC2B 6HP (GB) Babraham CB2 4AP (GB) • Pope, Anthony Richard Remarks: Cambridge CB1 2LW (GB) This application was filed on 08 - 03 - 2004 as a • Johnson, Kevin Stuart divisional application to the application mentioned Highfields, Cambridge CB3 7NY (GB) under INID code 62.
    [Show full text]
  • Antibody Discovery for Development of a Serotyping Dengue Virus NS1 Capture Assay
    Antibody Discovery for Development of a Serotyping Dengue Virus NS1 Capture Assay Kebaneilwe Lebani Master of Biotechnology (Advanced) A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2014 Australian Institute for Bioengineering and Nanotechnology ABSTRACT Dengue virus (DENV) infections are a significant public health burden in tropical and sub-tropical regions of the world. Infections are caused by four different but antigenically related viruses which result in four DENV serotypes. The multifaceted nature of DENV pathogenesis hinders the sensitivity of assays designed for the diagnosis of infection. Different markers can be optimally detected at different stages of infection. Of particular clinical importance is the identification of acute viremia during the febrile phase of infection which is pivotal for management of infection. Non-structural protein 1 (NS1) has been identified as a good early surrogate marker of infection with possible applications in epidemiological surveillance and the development of blood screening assays. This contribution is towards using serotype-specificity to achieve specific and more sensitive diagnostic detection of DENV NS1. The general aim of this work is to isolate immune-reagents that can be used to develop an assay with improved sensitivity of DENV NS1 detection in a diagnostic setting. In this work, we sought to isolate serotype-specific antibodies that discern discreet antigenic differences in NS1 from each DENV serotype. Additionally, we also sought to isolate a pairing antibody that recognises NS1 from all four DENV serotypes (pan-reactive) for tandem capture of the DENV NS1. To achieve this, three naive, immunoglobulin gene libraries (a VH domain, a scFv and a Fab library) were interrogated for binders to recombinant NS1 antigen from all four DENV serotypes using phage display technology and various biopanning approaches.
    [Show full text]
  • Molecular Cloning and Functional Expression of Gibberellin 2- Oxidases, Multifunctional Enzymes Involved in Gibberellin Deactivation
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 4698–4703, April 1999 Plant Biology Molecular cloning and functional expression of gibberellin 2- oxidases, multifunctional enzymes involved in gibberellin deactivation STEPHEN G. THOMAS,ANDREW L. PHILLIPS, AND PETER HEDDEN* Institute of Arable Crops Research (IACR)-Long Ashton Research Station, Department of Agricultural Sciences, University of Bristol, Long Ashton, Bristol BS41 9AF, United Kingdom Communicated by Jake MacMillan FRS, University of Bristol, Bristol, United Kingdom, February 16, 1999 (received for review December 22, 1998) ABSTRACT A major catabolic pathway for the gibberel- centration of bioactive GAs, the genes for these enzymes have lins (GAs) is initiated by 2b-hydroxylation, a reaction cata- not yet been isolated and it has not been possible to study their lyzed by 2-oxoglutarate-dependent dioxygenases. To isolate a regulation. GA 2b-hydroxylase cDNA clone we used functional screening Gibberellin 2b-hydroxylase activity is abundant in seeds of a cDNA library from developing cotyledons of runner bean during the later stages of maturation, particularly in legume (Phaseolus coccineus L.) with a highly sensitive tritium-release seeds, which accumulate large amounts of 2b-hydroxylated b assay for enzyme activity. The encoded protein, obtained by GAs (6–8). Indeed, GA8, the first 2 -hydroxyGA to be heterologous expression in Escherichia coli, converted GA9 to identified, was extracted from seeds of runner bean (Phaseolus b GA51 (2 -hydroxyGA9) and GA51-catabolite, the latter pro- coccineus, originally classified as P. multiflorus) (9). In certain duced from GA51 by further oxidation at C-2. The enzyme thus species, including legumes, further metabolism of 2b- is multifunctional and is best described as a GA 2-oxidase.
    [Show full text]
  • 3 Main Classification of Vectors (With Diagram)
    4/20/2020 3 Main Classification of Vectors (With Diagram) Privacy Policy | Join our Community :- Upload Now 3 Main Classification of Vectors (With Diagram) Article shared by : The classifications are: 1. On the Basis of Our Aim with Gene of Interest 2. On the Basis of Host Cell Used 3. On the Basis of Cellular Nature of Host Cell. Vector Classification # 1. On the Basis of Our Aim with Gene of Interest: The point is what we are targeting from our gene of interest — its multiple copies or its protein product. Depending on these criteria vec tors are of following two types: 1. Cloning Vectors: We use a cloning vec tor when our aim is to just obtain numer ous copies (clones) of our gene of interest (hence the name cloning vectors). These are mostly used in construction of gene libraries. A number of organisms can be used as sources for cloning vectors. Some are created synthetically, as in the case of yeast artificial chromosomes and bacte rial artificial chromosomes, while others are taken from bacteria and bacteriopha ges. In all cases, the vector needs to be genetically modified in order to accommo date the foreign DNA by creating an in sertion site where the new DNA will fit ted. Example: PUC cloning vectors, pBR322 cloning vectors, etc. 2. Expression Vectors or Expression construct: www.biotechnologynotes.com/recombinant-dna-technology/3-main-classification-of-vectors-with-diagram/395 1/64 4/20/2020 3 Main Classification of Vectors (With Diagram) We use an expression vector when our aim is to obtain the protein prod uct of our gene of interest.
    [Show full text]
  • Evolutionary and Functional Studies of the Mouse Retroviral Restriction Gene, Fvl
    Evolutionary and Functional Studies of the Mouse Retroviral Restriction Gene, Fvl Scott Anthony Ellis A thesis submitted in part fulfilment of the requirements of the University of London for the degree of Doctor of Philosophy March 2000 Virology Division National Institute for Medical Research The Ridgeway Mm Hill London NW71AA ProQuest Number: 10015911 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10015911 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Fvl is a gene of mice known to restrict the replication of Murine Leukaemia virus (MLV) by blocking integration by an unknown mechanism. The gene itself is retroviral in origin, and is located on the distal part of chromosome 4. The sequence of markers known to flank Fvl in the mouse was used to identify sequence from the human homologues of these 2 genes. The construction of primers to these sequences permitted the screening of 2 YAC and a PAC human genomic libraries for clones containing either of these genes. The YAC libraries were negative for both markers.
    [Show full text]
  • Muta-Gene@ Phagemid in Vitro Mutagenesis Version 2 Instruction Manual
    ~1~248cl 1/28/98 4:44 PM Page A f > Muta-Gene@ Phagemid In Vitro Mutagenesis Version 2 Instruction Manual + Catalog Number + 170-3581 For Technical Service Call Your Local Bio-Rad OffIce or in the U.S. Call 1-800 -4BIORAD (1-800-424-6723) ~11’248Cl 1/28/98 4:44 P1.1 Page i + Foreword This manual contains background information and detailed protocols for performing in vitro mutagenesis with the Muta-Gene phagemid in vitro mutagenesis kit. The mutagenesis technique described is intrinsically very easy to use. It requires only one enzymatic step; the two bacterial strains are healthy and easy to grow; and the efficiency of mutagenesis is usually sufficient that mutants can be identified by DNA sequence analysis rather than a phenotypic or hybridization screen. Bio-Rad’s kit provides reagents of the highest quality. All components have been rigorously tested in in vitro mutagenesis experiments. If you have any questions regard- ing the use of these products, please contact your local Bio-Rad representative or Bio- Rad’s Technical Services at 1-800-4BIORAD. These products are for research use only and not for use in humans or for diagnostic procedures. Safety precautions should be used when handling hazardous materials (radioac- tive nucleotides, acrylamide, ethidium bromide, phenol, chloroform, ether, etc.). Users of this kit should comply with NIH or other relevant guidelines for recombinant DNA work. L Y + +-- LIT248C1 1/28/98 5:12 PM Page ToC1 -+- Table of Contents Section 1 Introduction ...........................................................................l
    [Show full text]
  • Exploiting Light Chains for the Scalable Generation and Platform Purification
    ARTICLE Received 12 Nov 2014 | Accepted 15 Dec 2014 | Published 12 Feb 2015 DOI: 10.1038/ncomms7113 OPEN Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG Nicolas Fischer1,*, Greg Elson1,*,w, Giovanni Magistrelli1, Elie Dheilly1, Nicolas Fouque1, Ame´lie Laurendon1,w, Franck Gueneau1, Ulla Ravn1, Jean-Franc¸ois Depoisier1, Valery Moine1, Sylvain Raimondi1, Pauline Malinge1, Laura Di Grazia1, Franc¸ois Rousseau1, Yves Poitevin1,Se´bastien Calloud1, Pierre-Alexis Cayatte1, Mathias Alcoz1, Guillemette Pontini1,Se´verine Fage`te1,w, Lucile Broyer1, Marie Corbier1, Delphine Schrag1,Ge´rard Didelot1, Nicolas Bosson1, Nessie Costes1, Laura Cons1, Vanessa Buatois1, Zoe Johnson1, Walter Ferlin1, Krzysztof Masternak1 & Marie Kosco-Vilbois1 Bispecific antibodies enable unique therapeutic approaches but it remains a challenge to produce them at the industrial scale, and the modifications introduced to achieve bispecificity often have an impact on stability and risk of immunogenicity. Here we describe a fully human bispecific IgG devoid of any modification, which can be produced at the industrial scale, using a platform process. This format, referred to as a kl-body, is assembled by co-expressing one heavy chain and two different light chains, one k and one l. Using ten different targets, we demonstrate that light chains can play a dominant role in mediating specificity and high affinity. The kl-bodies support multiple modes of action, and their stability and pharmaco- kinetic properties are indistinguishable from therapeutic antibodies. Thus, the kl-body represents a unique, fully human format that exploits light-chain variable domains for antigen binding and light-chain constant domains for robust downstream processing, to realize the potential of bispecific antibodies.
    [Show full text]
  • Revolver Is a New Class of Transposon-Like Gene Composing the Triticeae Genome
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central DNA RESEARCH 15, 49–62, (2008) doi:10.1093/dnares/dsm029 Revolver is a New Class of Transposon-like Gene Composing the Triticeae Genome Motonori TOMITA*, Kasumi SHINOHARA, and Mayu MORIMOTO Molecular Genetics Laboratory, Faculty of Agriculture, Tottori University, 101, Koyama-minami 4-chome, Tottori City, Tottori 680-8553, Japan (Received 22 May 2007; accepted on 5 December 2007) Abstract Revolver discovered in the Triticeae plant is a novel class of transposon-like gene and a major com- ponent of the large cereal genome. An 89 bp segment of Revolver that is enriched in the genome of rye was isolated by deleting the DNA sequences common to rye and wheat. The entire structure of Revolver was determined by using rye genomic clones, which were screened by the 89 bp probe. Revolver consists of 2929—3041 bp with an inverted repeated sequence on each end and is dispersed through all seven chromosomes of the rye genome. Revolver is transcriptionally active, and the isolated full-length cDNA (726 bp) reveals that Revolver harbors a single gene consisting of three exons (342, 88, and 296 bp) and two introns (750 and 1237 bp), and encodes 139 amino acid residues of protein, which shows simi- larity to some transcriptional regulators. Revolver variants ranging from 2665 to 4269 bp, in which 50 regions were destructed, indicate structural diversities around the first exon. Revolver does not share iden- tity with any known class I or class II autonomous transposable elements of any living species.
    [Show full text]
  • Download Book
    Methods in Molecular Biology 1701 Michael Hust Theam Soon Lim Editors Phage Display Methods and Protocols M ETHODS IN M OLECULAR B IOLOGY Series Editor John M. Walker School of Life and Medical Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK For further volumes: http://www.springer.com/series/7651 Phage Display Methods and Protocols Edited by Michael Hust Technische Universit€at Braunschweig, Braunschweig, Germany Theam Soon Lim Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Minden, Penang, Malaysia Editors Michael Hust Theam Soon Lim Technische Universit€at Braunschweig Institute for Research in Molecular Medicine Braunschweig, Germany Universiti Sains Malaysia Minden, Penang, Malaysia ISSN 1064-3745 ISSN 1940-6029 (electronic) Methods in Molecular Biology ISBN 978-1-4939-7446-7 ISBN 978-1-4939-7447-4 (eBook) DOI 10.1007/978-1-4939-7447-4 Library of Congress Control Number: 2017956713 © Springer Science+Business Media LLC 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication.
    [Show full text]
  • Characterization of an RNA-Dependent RNA Polymerase Activity Associated with La France Isometric Virus†
    JOURNAL OF VIROLOGY, Mar. 1997, p. 2264–2269 Vol. 71, No. 3 0022-538X/97/$04.0010 Copyright q 1997, American Society for Microbiology Characterization of an RNA-Dependent RNA Polymerase Activity Associated with La France Isometric Virus† MICHAEL M. GOODIN,‡ BETH SCHLAGNHAUFER, TIFFANY WEIR, AND C. PETER ROMAINE* Department of Plant Pathology, Pennsylvania State University, University Park, Pennsylvania 16802 Received 12 August 1996/Accepted 19 November 1996 Purified preparations of La France isometric virus (LIV), an unclassified, double-stranded RNA (dsRNA) virus of Agaricus bisporus, were associated with an RNA-dependent RNA polymerase (RDRP) activity. RDRP activity cosedimented with the 36-nm isometric particles and genomic dsRNAs of LIV during rate-zonal centrifugation in sucrose density gradients, suggesting that the enzyme is a constituent of the virion. Enzyme activity was maximal in the presence of all four nucleotides, a reducing agent (dithiothreitol or b-mercapto- ethanol), and Mg21 and was resistant to inhibitors of DNA-dependent RNA polymerases (actinomycin D, a-amanitin, and rifampin). The radiolabeled enzyme reaction products were predominantly (95%) single- stranded RNA (ssRNA) as determined by cellulose column chromatography and ionic-strength-dependent sensitivity to hydrolysis by RNase A. Three major size classes of ssRNA transcripts of 0.95, 1.3, and 1.8 kb were detected by agarose gel electrophoresis, although the transcripts hybridized to all nine of the virion-associated dsRNAs. The RNA products synthesized in vitro appeared to be of a single polarity, as they hybridized to an ssDNA corresponding to one strand of a genomic dsRNA and not to the complementary strand.
    [Show full text]
  • Changes in Mitochondrial Stability During the Progression of the Barrett’S Esophagus Disease Sequence N
    O’Farrell et al. BMC Cancer (2016) 16:497 DOI 10.1186/s12885-016-2544-2 RESEARCH ARTICLE Open Access Changes in mitochondrial stability during the progression of the Barrett’s esophagus disease sequence N. J. O’Farrell1, R. Feighery1, S. L. Picardo1, N. Lynam-Lennon1, M. Biniecka2, S. A. McGarrigle1, J. J. Phelan1, F. MacCarthy3,D.O’Toole3, E. J. Fox4, N. Ravi1, J. V. Reynolds1 and J. O’Sullivan1* Abstract Background: Barrett’s esophagus follows the classic step-wise progression of metaplasia-dysplasia-adenocarcinoma. While Barrett’s esophagus is a leading known risk factor for esophageal adenocarcinoma, the pathogenesis of this disease sequence is poorly understood. Mitochondria are highly susceptible to mutations due to high levels of reactive oxygen species (ROS) coupled with low levels of DNA repair. The timing and levels of mitochondria instability and dysfunction across the Barrett’s disease progression is under studied. Methods: Using an in-vitro model representing the Barrett’s esophagus disease sequence of normal squamous epithelium (HET1A), metaplasia (QH), dysplasia (Go), and esophageal adenocarcinoma (OE33), random mitochondrial mutations, deletions and surrogate markers of mitochondrial function were assessed. In-vivo and ex-vivo tissues were also assessed for instability profiles. Results: Barrett’s metaplastic cells demonstrated increased levels of ROS (p < 0.005) and increased levels of random mitochondrial mutations (p < 0.05) compared with all other stages of the Barrett’s disease sequence in-vitro. Using patient in-vivo samples, Barrett’s metaplasia tissue demonstrated significantly increased levels of random mitochondrial deletions (p = 0.043) compared with esophageal adenocarcinoma tissue, along with increased expression of cytoglobin (CYGB) (p < 0.05), a gene linked to oxidative stress, compared with all other points across the disease sequence.
    [Show full text]
  • Genetic Mobility and Instability of Retroviral Vector in Vector Producer Cells for Gene Therapy Won-Bin Young Iowa State University
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1999 Genetic mobility and instability of retroviral vector in vector producer cells for gene therapy Won-Bin Young Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Genetics Commons, Microbiology Commons, and the Molecular Biology Commons Recommended Citation Young, Won-Bin, "Genetic mobility and instability of retroviral vector in vector producer cells for gene therapy" (1999). Retrospective Theses and Dissertations. 12196. https://lib.dr.iastate.edu/rtd/12196 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion.
    [Show full text]